The Liposome Company
Executive Summary
Due to continued growth in sales of Abelcet (amphotericin B lipid complex), TLC expects to show a profit for the first time in the company's history when fourth quarter results are released at the beginning of February, CEO Chuck Baker announced Jan. 13. For the nine months ended Sept. 30, 1998, Abelcet showed a 35% unit sales growth, with similar growth projected for the fourth quarter. TLC expects to be profitable for the full year in 1999, based on continued Abelcet sales and expected approval of the company's liposomal doxorubicin Evacet. The company filed a BLA for the metastatic breast cancer therapy Dec. 14. Results of the pivotal trials of Evacet show the drug to be equivalent to free doxorubicin in efficacy, but with significantly less cardiotoxicity. TLC plans to continue Evacet studies as a combination therapy with Bristol-Myers Squibb's Taxol, Rhone-Poulenc Rorer's Taxotere and Genentech's Herceptin, Baker said
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth